“Ukatamanga weka utamangisa, tikatamanga awili, tifikapatali" - When you run alone, you run fast. When you run together, you run fast - Zambian Proverb

UNZA-UCLMS

Research and Training Programme

Publications 2017/18

Tuberculosis: progress and advances in development of new drugs, treatment regimens, and host-directed therapies. Tiberi S, du Plessis N, Walzl G, Vjecha MJ, Rao M, Ntoumi F, Mfinanga S, Kapata N, Mwaba P, McHugh TD, Ippolito G, Migliori GB, Maeurer MJ, Zumla A. Lancet Infect Dis. 2018 Mar 23.


Tuberculosis: advances and challenges in development of new diagnostics and biomarkers. Walzl G, McNerney R, du Plessis N, Bates M, McHugh TD, Chegou NN, Zumla A. Lancet Infect Dis. 2018 Mar 23. pii: S1473-3099(18)30111-7. doi: 10.1016/S1473-3099(18)30111-7.


Concrete action now: UN High-Level Meeting on Tuberculosis. Herbert N, Sharma V, Masham BS, Sheehan BS, Hauser J, Zumla A. Lancet Infect Dis. 2018 Mar 23. pii: S1473-3099(18)30171-3.


Taking forward the Stop TB Partnership and World Health Organization Joint Theme for World TB Day March 24th 2018 - "Wanted: Leaders for a TB-Free World. You can make history. End TB". Tiberi S, Petersen E, Maeurer M, Ntoumi F, Yeboa-Manu D, Mwaba P, Vilaplana C, Dar O, Bates M, Corrah T, Rao M, Kapata N, Azhar EI, Memish ZA, Mfinanga S, Aseffa A, Ippolito G, Migliori GB, Zumla A.

Int J Infect Dis. 2018 Mar 22.


The critically ill patient with tuberculosis in intensive care: Clinical presentations, management and infection control. Otu A, Hashmi M, Mukhtar AM, Kwizera A, Tiberi S, Macrae B, Zumla A, Dünser MW, Mer M. J Crit Care. 2018 Mar 13;45:184-196.


Accelerating the development of therapeutic strategies for drug-resistant tuberculosis. Vjecha MJ, Tiberi S, Zumla A. Nat Rev Drug Discov. 2018 Mar 23.


Urgent need for multi-site controlled trials for CMV pneumonia treatment in African children. Tembo J, Moraleda C, Rojo P, Zumla A, Bates M. Int J Tuberc Lung Dis. 2018 Apr 1;22(4):469-470.


Evaluation of the efficacy of valproic acid and suberoylanilide hydroxamic acid (vorinostat) in enhancing the effects of first-line tuberculosis drugs against intracellular Mycobacterium tuberculosis. Rao M, Valentini D, Zumla A, Maeurer M. Int J Infect Dis. 2018 Mar 2;69:78-84.


Is there sufficient evidence to repeal three decades of clinical research on chronic hepatitis C? Ippolito G, Zumla A, Lanini S. Clin Microbiol Infect. 2018 Jan 8.


Relationship Between Viremia and Specific Organ Damage in Ebola Patients: A Cohort Study. Lanini S, Portella G, Vairo F, Kobinger GP, Pesenti A, Langer M, Kabia S, Brogiato G, Amone J, Castilletti C, Miccio R, Capobianchi MR, Strada G, Zumla A, Di Caro A, Ippolito G; INMI-EMERGENCY EBOV Sierra Leone Study Group. Clin Infect Dis. 2018 Jan 6;66(1):36-44.



For a complete list of our high profile Journal Theme Series from 1999-2018, click here

Publications Summary 1982-2018
 
Lancet
50
Int J infect Dis
53
Lancet Infect Dis
48
Curr Opin Pulm Med
32
J Infect Dis
20
Clin Infect Dis
17
PLoS One
16
Trop Med Int Health
15
Eur Respir J
14
Lancet Resp Med
14
Int J Tuberc Lung Dis
13
Am J Respir Crit Care Med
10
N Eng J Med
8
BMJ
8
J Infect
7
S Afr Med J
7
Infect Dis Clin North Am
6
Nature Rev. Drug. Dis
4
J Clin Microbiol  
5
Postgrad Med J
5
Clin Microbiol Infect
5
BMC Med
4
AIDS
4
Clin Chest Med 
J Antimicrob Chemotherapy
4
J R Soc Med 
Thorax
4
Trans R Soc Trop Med Hyg
4
Tuberculosis (Edinb) 
Other
116
 TOTAL
517